STOCK TITAN
  1. Home
  2. News
  3. CPRX

Catalyst Pharmaceuticals Inc - CPRX STOCK NEWS

Welcome to our dedicated news page for Catalyst Pharmaceuticals (Ticker: CPRX), a resource for investors and traders seeking the latest updates and insights on Catalyst Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Catalyst Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Catalyst Pharmaceuticals's position in the market.

News
Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023
Rhea-AI Summary
Catalyst Pharmaceuticals to release Q3 2023 financial results and host conference call and webcast on November 9, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
conferences earnings
-
News
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
Rhea-AI Summary
Catalyst Pharmaceuticals announces the appointment of Richard J. Daly as the new CEO, effective January 1, 2024. Patrick J. McEnany will retire as CEO but continue as Chairman of the Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
management
-
News
Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®
Rhea-AI Summary
Catalyst Pharmaceuticals' sNDA for FIRDAPSE accepted by FDA for review
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
clinical trial
News
Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
Rhea-AI Summary
Catalyst Pharmaceuticals announces participation in 2023 Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
conferences
-
News
Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
Rhea-AI Summary
Catalyst Pharmaceuticals announces that a study reveals a significant underdiagnosis of Lambert-Eaton myasthenic syndrome (LEMS) in US patients with small cell lung cancer (SCLC). While previous estimates suggest that 3% of SCLC patients have LEMS, this study found that only 0.16-0.24% of SCLC patients had LEMS claims, indicating a 10-fold underdiagnosis. The study suggests that non-specific LEMS symptoms may have been attributed to SCLC, leading to underdiagnosis. The prevalence of LEMS is now estimated to be 3,600 to 5,400 people in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
none
-
News
Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. (CPRX) announces multiple abstracts on FYCOMPA® (perampanel) CIII to be presented at the 35th International Epilepsy Congress, highlighting its use in treating focal and generalized epilepsy in diverse patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
News
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Catalyst Pharmaceuticals achieves record Q2 2023 total net revenues of $99.6 million, with a 22% YoY increase in FIRDAPSE net revenues. They also report a Q2 GAAP EPS diluted of $0.33 compared to $0.20 for Q2 2022. The company completed the acquisition of the North American license for Vamorolone and submitted an sNDA for FIRDAPSE seeking to increase the maximum indicated dose. They have raised their full-year 2023 total revenue guidance to between $380 million and $390 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.37%
Tags
earnings
-
News
Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End
Rhea-AI Summary
Catalyst Pharmaceuticals announces that Patrick J. McEnany, Co-Founder, Chairman, and CEO, will retire from his position by the end of 2023. He will continue to serve as non-Executive Chairman of the Board. The Board has initiated a search for his successor as CEO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
-
News
Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. will release its second-quarter 2023 financial results on August 9, 2023, and host a conference call and webcast on August 10, 2023, to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
conferences earnings
News
Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
Rhea-AI Summary
Catalyst Pharmaceuticals has acquired an exclusive license for North America for vamorolone, a potential treatment for Duchenne Muscular Dystrophy (DMD). Vamorolone has shown efficacy in clinical studies with reduced side effects and benefits for DMD patients. The drug has received FDA Orphan Drug and Fast Track designations, with a PDUFA action date of October 26, 2023. Catalyst expects to launch vamorolone in the U.S. early in Q1 2024, subject to regulatory approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
acquisition
Stock CPRX logo
Catalyst Pharmaceuticals Inc

Nasdaq:CPRX

CPRX Rankings

#1986 Ranked by Market Cap
#2926 Ranked by Stock Gains
N/A Ranked by Dividends

CPRX Stock Data

1.80B
101.40M
6.21%
73.15%
5.14%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Coral Gables

About CPRX

catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso